Craft

Advanced
Celyad

Celyad

Stock Price

€0.3

2024-10-29

Market Capitalization

€10.9 M

2024-10-29

Revenue

€102 K

FY, 2023

Celyad Summary

Company Summary

Overview
Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.
Type
Public
Status
Active
Founded
2007
HQ
Mont-Saint-Guibert, BE | view all locations
Website
http://www.celyad.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Michel Lussier

    Michel Lussier, Chairman, Non-Executive Director

    • Frederic Lehmann

      Frederic Lehmann, VP Clinical Development and Medical Affairs

      • Marina Udier, Independent Director

        • Serge Goblet

          Serge Goblet, Non-Executive Director

          LocationsView all

          2 locations detected

          • Mont-Saint-Guibert, Wallonie HQ

            Belgium

            2 Rue Edouard Belin

          • New York, NY

            United States

            60 Broad St Suite 3502

          Celyad Financials

          Summary Financials

          Revenue (H1, 2024)
          €14.0K
          Gross profit (H1, 2024)
          €262.0K
          Net income (H1, 2024)
          (€3.0M)
          Cash (H1, 2024)
          €6.2M
          EBIT (H1, 2024)
          (€3.1M)
          Enterprise value
          $5.7M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2025
          Share price data provided by IEX